VivoSeq
Oncology

Germ Cell Tumor

75

Pipeline Programs↗

10

Active Trials↗

29

Companies Involved↗

Germ Cell Tumor is a moderately active landscape with 75 programs across 29 companies. The most active players are Astex Pharmaceuticals, Inc., Sanofi, Merck & Co.. 5 therapies are approved with 14 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

66/100

Pipeline Velocity

6/100

Mech. Concentration

14/100

Completion Rate

72/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Astex Pharmaceuticals, Inc.

1 program

Phase 1Sanofi logo

Sanofi

4 programs

Phase 2Merck & Co. logo

Merck & Co.

3 programs

Phase 2G

Gynecologic Oncology Group

3 programs

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

2 programs

Phase 2Amgen logo

Amgen

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

86%

Small molecule

66 of 77 classified programs — the dominant modality here.

14%ALL OTHERSMonoclonal antibody56%Protein / enzyme45%Antibody–drug conjugate11%Vaccine11%

Small molecule leads; the ring shows all 77 classified programs, each share of the total. Modality classified for 100% of 82 pipeline programs.

Analysis

Trial Status

74

clinical trials

Completed39 · 53%
Terminated13 · 18%
Unknown status10 · 14%
Recruiting8 · 11%
Withdrawn2 · 3%
Active, not recruiting2 · 3%

Clinical Trials

Trial Activity

74 trials

The Efficacy of WVI in Patients With Localized Basal Ganglia Intracranial Germ Cell Tumors
Recruiting·—·Phase 2·NCT05124951·150 enrolled
TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors
Recruiting·—·Phase 3·NCT02429687·129 enrolled
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Recruiting·Children's Oncology Group·Phase 3·NCT03067181·1,780 enrolled
Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin.
Recruiting·—·Phase 2·NCT07188441·40 enrolled
High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors
Recruiting·NN.N. Petrov National Medical Research Center of Oncology·Phase 2·NCT06418789·25 enrolled
Evaluation of Bile Acid Concentrations and Their Signaling as Markers of Testicular Tumorigenesis and Germ Cell Tumor Chemosensitivity
Recruiting·UUniversity Hospital, Clermont-Ferrand·N/A·NCT07463508·20 enrolled
Paclitaxel/Ifosfamide/Cisplatin Chemotherapy for High Risk Pediatric Germ Cell Tumor
Recruiting·YYonsei University·Phase 2·NCT05455918·42 enrolled
Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors
Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT05874063·387 enrolled
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03158064·30 enrolled
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
Active, not recruiting·Alliance for Clinical Trials in Oncology·Phase 3·NCT02375204·420 enrolled
Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors
Completed·Children's Oncology Group·Phase 2·NCT00002594·31 enrolled
Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors
Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02161692
Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Completed·National Cancer Institute (NCI)·Phase 2·NCT00957905·36 enrolled
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
Completed·—·Phase 2·NCT01736917·65 enrolled
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
Completed·Children's Oncology Group·Phase 3·NCT00716976·131 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)